Crossmark

Comparative Preclinical Pharmacokinetics and Disposition of Favipiravir Following Pulmonary and Oral Administration as Potential Adjunct Therapy Against Airborne RNA Viruses

Crossref DOI link: https://doi.org/10.1007/s11095-024-03782-3

Published Online: 2024-10-17

Published Print: 2024-11

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Devireddy, Venkata Siva Reddy

Shafi, Hasham

Verma, Sonia

Singh, Sanjay

Chakradhar, J. V. U. S.

Kothuri, Naresh

Bansode, Himanshu

Raman, Sunil Kumar

Sharma, Deepak

Azmi, Lubna

Verma, Rahul Kumar

Misra, Amit https://orcid.org/0000-0001-5503-0694
Funding

Funding for this research was provided by:

CSIR-Central Drug Research Institute (MLP0016)
License Information

Text and Data Mining valid from 2024-10-17

Version of Record valid from 2024-10-17
More Information

Article History

Received: 8 July 2024

Accepted: 6 October 2024

First Online: 17 October 2024

Declarations

:

: None to declare.

: No generative AI was used for any purpose.

Document is current

Any future updates will be listed below